secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001193125-24-002523
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics appoints Dr. Michael B. Atkins, cancer immunotherapy expert, to board
--------------------------------------------------------------------------------

- Dr. Atkins appointed as Class III director effective Jan. 4, 2024; will serve until 2024 annual meeting.
- He brings over 30 years of translational and clinical research in melanoma, kidney cancer, and immunotherapy.
- Appointed to Nominating and Corporate Governance Committee.
- Receives annual cash compensation of $40,000 plus $4,000 committee fee; granted option for 35,000 shares at $5.25.
- Option vests one-third on first anniversary, then monthly over three years, subject to continued service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312524002523/0001193125-24-002523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312524002523/d705253d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-002523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer